NEW YORK (GenomeWeb News) - Agilent Technologies said late yesterday that fiscal second-quarter revenues increased 6 percent as R&D spending increased 1 percent and profit climbed 7 percent.
Revenue for the company's Bio-Analytical Measurement segment increased 15 percent to $428 million from $372 million year over year and Life Sciences revenue was up 20 percent to $194 million, the company said.
The company attributed the growth to strong sales of liquid chromatography and LC/mass spectrometry instruments and its comparative genomic hybridization microarrays.
Total receipts for the three months ended April 31 increased to $1.32 billion from $1.24 billion year over year.
R&D spending increased to $173 million from $172 million year over year.
The company said net income rose to $123 million from $115 million in the year-ago period.
Agilent said it had around $2.05 billion in cash and cash equivalents as of April 31.
For the third quarter of 2007, the company said it expects revenues between $1.36 billion and $1.4 billion.